IMV Inc. is a clinical-stage immuno-oncology company advancing a portfolio of therapies based on the Company’s immune-educating platform: the DPX® technology. Through a differentiated mechanism...

BioVaxys Technology Corp, a leader in biopharmaceutical innovation focused on antiviral and cancer vaccine development. Leveraging our recent acquisition of IMV INC's IP, we're at the forefront of advancing DPX™ delivery technology and haptenized protein vaccines, targeting solid tumors and various viral infections.

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid...

2019年7月13日 · IMV Inc. (NASDAQ:IMV)创立于2000年，前称Immunovaccine Inc.，于2018年5月改为现用名，总部位于简答Dartmouth，全职雇员63人，是一家临床阶段的免疫肿瘤学公司，与其子公司一起，开发基于其平台和产品的产品，主要专注于癌症的T细胞激活疗法。 IMV是一家临床阶段的免疫肿瘤学公司，希望改变人类免疫力的方式，以解决当今医学领域中一些最复杂，最具破坏性的疾病。 IMV公司的DPX药物开发平台提供专利的递送配方，可以控制和长期将抗原暴 …

了解IMV, Inc. (IMV, Inc.)公司的药物管线，治疗领域，技术平台，以及它的11项临床试验, 18篇新闻和15篇文献，疾病领域:肿瘤，内分泌与代谢疾病，神经系统疾病，血液及淋巴系统疾病，免疫系统疾病，感染，技术平台:治疗性疫苗，小分子化药，通用抗原疫苗，合成 ...

Get the latest IMV Inc. (IMVIF) stock price quote with financials, statistics, dividends, charts and more.

2025年3月4日 · IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers.

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.

IMV Inc Inc. applies its novel adjuvanting platform to the development of vaccines for cancer therapy, infectious diseases and animal health. The Company’s DepoVax™ platform is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system.

2025年3月5日 · A high-level overview of IMV Inc. (IMVIF) stock. View (IMVIF) real-time stock price, chart, news, analysis, analyst reviews and more.